NCT07167446View on ClinicalTrials.gov

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

September 5, 2027

Study Completion Date

September 7, 2028

Conditions
Oxaliplatin Induced Peripheral Neuropathy in Cancer PatientsMetastatic Colorectal Cancer (CRC)Peripheral Neuropathy Due to Chemotherapy
Interventions
DRUG

Cannabidiol (CBD)

Oral hemp-derived CBD capsules, 150 mg twice daily (with titration in Cycle 1; dose reductions permitted for tolerability). Administered starting the day before oxaliplatin infusion and continued for 7 days after each chemotherapy cycle.

DRUG

oxaliplatin-based chemotherapy

Standard of care oxaliplatin-based regimens per NCCN guidelines (e.g., FOLFOX or CAPEOX), administered in 2-3 week cycles for a maximum of 6 months.

Trial Locations (1)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER